// App-Quantinova.ai

TPS349 : A phase III, double-blind, randomized study of nivolumab (NIVO) and ipilimumab (IPI), nivo monotherapy or placebo plus transarterial chemoembolization (TACE) in patients with intermediate-stage hepatocellular carcinoma (HCC).

Researchers

Presenter

  • Bruno Sangro

Principal Investigators

  • James J. Harding

  • Matthew Johnson

  • Daniel H. Palmer

  • Julien Edeline

  • Ghassan K. Abou-Alfa

  • Ann-Lii Cheng

  • Thomas Decaens

  • Anthony B. El-Khoueiry

  • Richard S. Finn

  • Peter R. Galle

  • Joong-Won Park

  • Thomas Yau

  • Damir Begic

  • Yun Shen

  • Jaclyn Neely

  • Ashwin Reddy Sama

  • Masatoshi Kudo

Medical Centers

  • Clinica Universidad de Navarra, Pamplona, Spain

  • Department of Surgery, Gynecologic Service, Memorial Sloan-Kettering Cancer Center, New York, NY

  • Department of Radiology and Imaging Sciences, Indiana University School of Medicine, Indianapolis, IN

  • Liverpool Experimental Cancer Medicine Centre, University of Liverpool, and the Clatterbridge Cancer Centre, Liverpool, United Kingdom

  • Centre Eugene-Marquis, Rennes, France

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

  • Department of Gastroenterology and Hepatology, Université Grenoble Alpes, INSERM U1209, Grenoble, France

  • USC Norris Comprehensive Cancer Center, Los Angeles, CA

  • David Geffen School of Medcn at UCLA, Los Angeles, CA

  • University Medical Center Mainz, Mainz, Germany

  • Center for Liver Cancer, National Cancer Center, Goyang, Korea

  • University of Hong Kong, Hong Kong, China

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Niigata University School of Medicine, Niigata, Japan

Locations

  • Spain

  • United States

  • United Kingdom

  • France

  • Taiwan

  • Germany

  • Republic of South Korea

  • China

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Liver cancer

Biomarkers

  • N/A

Drug/Treatment

  • Ipilimumab

  • Nivolumab

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

  • Multiple Arm

  • Controlled

Phase

  • III

Study Id's

  • NCT04340193

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved